Abstract: The object of the invention are monoclonal antibodies against hemagglutinin of H5-serotype influenza viruses selected from the group comprising G-1-31-22, G-2-14-10, G-5-32-5, G-6-42-42, G-7-24-17 and G-7-27-18, having a broad application in immunoprophyiaxis and immunotherapy of infections evoked by H5-serotype influenza viruses in humans and animals. The invention also provides hybridomas producing said antibodies, as well as compositions and diagnostic kits containing said antibodies for the detection and typing of H5-serotype influenza viruses and antibodies against H5-serotype influenza viruses in biological samples.

Abstract: The invention relates to an influenza viruses hemagglutinin protein as a vaccine antigen against influenza viruses, in particular to a protein being a fragment of H5 hemagglutinin from highly pathogenic avian influenza virus (HPAIV) H5N1 strain, expressed in a bacterial expression system. The protein according to the invention is a potential ingredient of an anti-HPAIV H5N1 vaccine, administered to chickens parenterally or through mucous membranes in the presence of adjuvants. The object of the invention is also a method of obtaining the vaccine protein.

Abstract: The invention relates to an influenza viruses hemagglutinin protein as a vaccine antigen against influenza viruses, in particular to a protein being a fragment of H5 hemagglutinin from highly pathogenic avian influenza virus (HPAIV) H5N1 strain, expressed in a bacterial expression system. The protein according to the invention is a potential ingredient of an anti-HPAIV H5N1 vaccine, administered to chickens parenterally or through mucous membranes in the presence of adjuvants. The object of the invention is also a method of obtaining the vaccine protein.

Abstract: The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterised by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called “sawteeth effect”, during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g.

Abstract: A UBP1 protease mutant and the sequence coding it, their application and products and the methods used to produce them may be used in the production of recombinant proteins, particularly on an industrial scale.

Abstract: The subject matters of invention relate to expression cassette, use of the expression cassette, expression vector, prokaryotic host cell harbouring expression vector, bacterial strain, and method for producing a polypeptide. In more detail, the invention relate to stable expression of recombinant polypeptides, in systems with no need of using antibiotics. Particularly, stable expression of recombinant proteins obtained with the use of very efficient T7 polymerase/promoter system.

Abstract: New biosynthetic analogues of recombined human insulin of prolonged therapeutical activity, which can find place in prophylactic and treatment of diabetes.

Abstract: The subject matters of invention relate to expression cassette, use of the expression cassette, vector, host cell, a method for producing a polypeptide ensuring its stable expression by the prokaryotic host as well as an use of the expression cassette. The invention enables stable expression of the target polypeptide, in systems where DNA-dependent RNA polymerase recognizes promoter regulating synthesis of target protein as well as selection marker, which is required for survival of the host.

Abstract: New biosynthetic analogues of recombined human insulin of prolonged therapeutical activity, which can find place in prophylactic and treatment of diabetes.

Abstract: Invention relates to novel and improved UBP1 protease mutants with a substitution at position (754), a deletion of amino-acids at position (1-54) and at least a portion of the amino-acids found at position (55-98) and their coding sequence as well as their applications and heterogonous protein expression system comprising thereof.

Abstract: New biosynthetic analogues of recombined human insulin of prolonged therapeutical activity, which can find place in prophylactic and treatment of diabetes.

Abstract: A method of producing somatotropin encompassing the microbiological expression of a recombinant protein containing somatotropin and hybrid polypeptide containing the amino-acid sequence of ubiquitin and the amino-acid sequence of somatotropin.

Abstract: A method is described of obtaining a plasmid contained in a difficult to separate, heterogenous plasmid DNA fraction, particularly one containing various plasmids of similar sizes. Another aspect of the present invention are new plasmids obtained via the method according to the present invention, their derivatives and/or fragments, as well as the application of these products in biotechnology and medicine, particularly gene therapy.

Abstract: The described binary vector with containing the expression cassette of the S-HBsAg protein under the control of the constitutive 35S promoter as well as the method of transforming lettuce using a strain of Agrobacterium tumefaciens containing the vector, facilitate the production of plant material for the manufacture of an oral HepB vaccine.

Abstract: The subject matters of invention relate to expression cassette, use of the expression cassette, vector, host cell, a method for producing a polypeptide ensuring its stable expression by the prokaryotic host as well as an use of the expression cassette. The invention enables stable expression of the target polypeptide, in systems where DNA-dependent RNA polymerase recognises promoter regulating synthesis of target protein as well as selection marker, which is required for survival of the host.

Abstract: A method of producing somatotropin encompassing the microbiological expression of a recombinant protein containing somatotropin and hybrid polypeptide containing the amino-acid sequence of ubiquitin and the amino-acid sequence of somatotropin.

Abstract: Invention relates to novel and improved UBP1 protease mutants with a substitution at position (754), a deletion of amino-acids at position (1-54) and at least a portion of the amino-acids found at position (55-98) and their coding sequence as well as their applications and heterogonous protein expression system comprising thereof.

Abstract: A method is described of obtaining a plasmid contained in a difficult to separate, heterogenous plasmid DNA fraction, particularly one containing various plasmids of similar sizes. Another aspect of the present invention are new plasmids obtained via the method according to the present invention, their derivatives and/or fragments, as well as the application of these products in biotechnology and medicine, particularly gene therapy.

Abstract: A UBP1 protease mutant and the sequence coding it, their application and products and the methods used to produce them may be used in the production of recombinant proteins, particularly on an industrial scale.